Global and China Atypical Hemolytic Uremic Syndrome Drug Market Insights, Forecast to 2026
Table of Contents1 Study Coverage
1.1 Atypical Hemolytic Uremic Syndrome Drug Product Introduction
1.2 Market Segments
1.3 Key Atypical Hemolytic Uremic Syndrome Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Type
1.4.2 ALN-CC5
1.4.3 CCX-168
1.4.4 ET-006
1.4.5 ETR-001
1.4.6 Mubodina
1.4.7 OMS-72
1.4.8 Others
1.5 Market by Application
1.5.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size, Estimates and Forecasts
2.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue 2015-2026
2.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales 2015-2026
2.2 Global Atypical Hemolytic Uremic Syndrome Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Atypical Hemolytic Uremic Syndrome Drug Historical Market Size by Region (2015-2020)
2.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Atypical Hemolytic Uremic Syndrome Drug Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Forecast by Region (2021-2026)
2.4.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Forecast by Region (2021-2026)
3 Global Atypical Hemolytic Uremic Syndrome Drug Competitor Landscape by Players
3.1 Global Top Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers
3.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers by Revenue
3.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Atypical Hemolytic Uremic Syndrome Drug Revenue in 2019
3.2.5 Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Manufacturers
3.4 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturing Base Distribution, Product Types
3.4.1 Atypical Hemolytic Uremic Syndrome Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Atypical Hemolytic Uremic Syndrome Drug Product Type
3.4.3 Date of International Manufacturers Enter into Atypical Hemolytic Uremic Syndrome Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Type (2015-2020)
4.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2015-2020)
4.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2015-2020)
4.1.3 Atypical Hemolytic Uremic Syndrome Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Atypical Hemolytic Uremic Syndrome Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Forecast by Type (2021-2026)
4.2.3 Atypical Hemolytic Uremic Syndrome Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Application (2015-2020)
5.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2015-2020)
5.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2015-2020)
5.1.3 Atypical Hemolytic Uremic Syndrome Drug Price by Application (2015-2020)
5.2 Atypical Hemolytic Uremic Syndrome Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Price Forecast by Application (2021-2026)
6 China by Players, Type and Application
6.1 China Atypical Hemolytic Uremic Syndrome Drug Market Size YoY Growth 2015-2026
6.1.1 China Atypical Hemolytic Uremic Syndrome Drug Sales YoY Growth 2015-2026
6.1.2 China Atypical Hemolytic Uremic Syndrome Drug Revenue YoY Growth 2015-2026
6.1.3 China Atypical Hemolytic Uremic Syndrome Drug Market Share in Global Market 2015-2026
6.2 China Atypical Hemolytic Uremic Syndrome Drug Market Size by Players (International and Local Players)
6.2.1 China Top Atypical Hemolytic Uremic Syndrome Drug Players by Sales (2015-2020)
6.2.2 China Top Atypical Hemolytic Uremic Syndrome Drug Players by Revenue (2015-2020)
6.3 China Atypical Hemolytic Uremic Syndrome Drug Historic Market Review by Type (2015-2020)
6.3.1 China Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2015-2020)
6.3.2 China Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2015-2020)
6.3.3 China Atypical Hemolytic Uremic Syndrome Drug Price by Type (2015-2020)
6.4 China Atypical Hemolytic Uremic Syndrome Drug Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Atypical Hemolytic Uremic Syndrome Drug Sales Forecast by Type (2021-2026)
6.4.2 China Atypical Hemolytic Uremic Syndrome Drug Revenue Forecast by Type (2021-2026)
6.4.3 China Atypical Hemolytic Uremic Syndrome Drug Price Forecast by Type (2021-2026)
6.5 China Atypical Hemolytic Uremic Syndrome Drug Historic Market Review by Application (2015-2020)
6.5.1 China Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2015-2020)
6.5.2 China Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2015-2020)
6.5.3 China Atypical Hemolytic Uremic Syndrome Drug Price by Application (2015-2020)
6.6 China Atypical Hemolytic Uremic Syndrome Drug Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Atypical Hemolytic Uremic Syndrome Drug Sales Forecast by Application (2021-2026)
6.6.2 China Atypical Hemolytic Uremic Syndrome Drug Revenue Forecast by Application (2021-2026)
6.6.3 China Atypical Hemolytic Uremic Syndrome Drug Price Forecast by Application (2021-2026)
7 North America
7.1 North America Atypical Hemolytic Uremic Syndrome Drug Market Size YoY Growth 2015-2026
7.2 North America Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
7.2.1 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2015-2020)
7.2.2 North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size YoY Growth 2015-2026
8.2 Europe Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
8.2.1 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country
8.2.2 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Size YoY Growth 2015-2026
9.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
9.2.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2015-2020)
9.2.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Atypical Hemolytic Uremic Syndrome Drug Market Size YoY Growth 2015-2026
10.2 Latin America Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
10.2.1 Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Country
10.2.2 Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
11.2.1 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country
11.2.2 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Achillion Pharmaceuticals Inc
12.1.1 Achillion Pharmaceuticals Inc Corporation Information
12.1.2 Achillion Pharmaceuticals Inc Description and Business Overview
12.1.3 Achillion Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.1.5 Achillion Pharmaceuticals Inc Recent Development
12.2 Akari Therapeutics Plc
12.2.1 Akari Therapeutics Plc Corporation Information
12.2.2 Akari Therapeutics Plc Description and Business Overview
12.2.3 Akari Therapeutics Plc Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.2.5 Akari Therapeutics Plc Recent Development
12.3 Alexion Pharmaceuticals Inc
12.3.1 Alexion Pharmaceuticals Inc Corporation Information
12.3.2 Alexion Pharmaceuticals Inc Description and Business Overview
12.3.3 Alexion Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.3.5 Alexion Pharmaceuticals Inc Recent Development
12.4 Amgen Inc
12.4.1 Amgen Inc Corporation Information
12.4.2 Amgen Inc Description and Business Overview
12.4.3 Amgen Inc Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.4.5 Amgen Inc Recent Development
12.5 ChemoCentryx Inc
12.5.1 ChemoCentryx Inc Corporation Information
12.5.2 ChemoCentryx Inc Description and Business Overview
12.5.3 ChemoCentryx Inc Sales, Revenue and Gross Margin (2015-2020)
12.5.4 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.5.5 ChemoCentryx Inc Recent Development
12.6 greenovation Biotech GmbH
12.6.1 greenovation Biotech GmbH Corporation Information
12.6.2 greenovation Biotech GmbH Description and Business Overview
12.6.3 greenovation Biotech GmbH Sales, Revenue and Gross Margin (2015-2020)
12.6.4 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.6.5 greenovation Biotech GmbH Recent Development
12.7 Kedrion SpA
12.7.1 Kedrion SpA Corporation Information
12.7.2 Kedrion SpA Description and Business Overview
12.7.3 Kedrion SpA Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.7.5 Kedrion SpA Recent Development
12.8 Omeros Corp
12.8.1 Omeros Corp Corporation Information
12.8.2 Omeros Corp Description and Business Overview
12.8.3 Omeros Corp Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.8.5 Omeros Corp Recent Development
12.11 Achillion Pharmaceuticals Inc
12.11.1 Achillion Pharmaceuticals Inc Corporation Information
12.11.2 Achillion Pharmaceuticals Inc Description and Business Overview
12.11.3 Achillion Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Products Offered
12.11.5 Achillion Pharmaceuticals Inc Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Atypical Hemolytic Uremic Syndrome Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Atypical Hemolytic Uremic Syndrome Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of TablesTable 1. Atypical Hemolytic Uremic Syndrome Drug Market Segments
Table 2. Ranking of Global Top Atypical Hemolytic Uremic Syndrome Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of ALN-CC5
Table 5. Major Manufacturers of CCX-168
Table 6. Major Manufacturers of ET-006
Table 7. Major Manufacturers of ETR-001
Table 8. Major Manufacturers of Mubodina
Table 9. Major Manufacturers of OMS-72
Table 10. Major Manufacturers of Others
Table 11. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 12. Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 13. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Regions 2015-2020 (K Pcs)
Table 14. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Regions (2015-2020)
Table 15. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Atypical Hemolytic Uremic Syndrome Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 17. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 18. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Manufacturers (2015-2020)
Table 19. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Atypical Hemolytic Uremic Syndrome Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Atypical Hemolytic Uremic Syndrome Drug as of 2019)
Table 21. Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Atypical Hemolytic Uremic Syndrome Drug Price (2015-2020) (USD/Pcs)
Table 24. Atypical Hemolytic Uremic Syndrome Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Atypical Hemolytic Uremic Syndrome Drug Product Type
Table 26. Date of International Manufacturers Enter into Atypical Hemolytic Uremic Syndrome Drug Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2015-2020) (K Pcs)
Table 29. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2015-2020)
Table 30. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2015-2020)
Table 32. Atypical Hemolytic Uremic Syndrome Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 33. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2021-2026)
Table 34. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2015-2020) (K Pcs)
Table 35. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2015-2020)
Table 36. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2021-2026)
Table 37. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share Forecast by Application (2021-2026)
Table 38. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2015-2020) (US$ Million)
Table 39. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share Forecast by Application (2021-2026)
Table 40. China Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) of Key Companies (2015-2020)
Table 41. China Atypical Hemolytic Uremic Syndrome Drug Sales Share by Company (2015-2020)
Table 42. China Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) by Company (2015-2020)
Table 43. China Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) by Type (2015-2020)
Table 44. China Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2015-2020)
Table 45. China Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 46. China Atypical Hemolytic Uremic Syndrome Drug Price (K Pcs) by Type (2015-2020)
Table 47. China Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) by Type (2021-2026)
Table 48. China Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2021-2026)
Table 49. China Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 50. China Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2021-2026)
Table 51. China Atypical Hemolytic Uremic Syndrome Drug Price (K Pcs) by Type (2021-2026)
Table 52. China Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) by Application (2015-2020)
Table 53. China Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2015-2020)
Table 54. China Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 55. China Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) by Application (2021-2026)
Table 56. China Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2021-2026)
Table 57. China Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 58. China Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2021-2026)
Table 59. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2015-2020) (K Pcs)
Table 60. North America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2015-2020)
Table 61. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2015-2020) (US$ Million)
Table 62. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2015-2020)
Table 63. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2015-2020) (K Pcs)
Table 64. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2015-2020)
Table 65. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2015-2020) (US$ Million)
Table 66. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2015-2020)
Table 67. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2015-2020) (K Pcs)
Table 68. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2015-2020)
Table 69. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2015-2020) (US$ Million)
Table 70. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2015-2020)
Table 71. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2015-2020) (K Pcs)
Table 72. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2015-2020)
Table 73. Latin Americaa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2015-2020) (US$ Million)
Table 74. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2015-2020)
Table 75. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2015-2020) (K Pcs)
Table 76. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2015-2020)
Table 77. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2015-2020) (US$ Million)
Table 78. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2015-2020)
Table 79. Achillion Pharmaceuticals Inc Corporation Information
Table 80. Achillion Pharmaceuticals Inc Description and Business Overview
Table 81. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 82. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product
Table 83. Achillion Pharmaceuticals Inc Recent Development
Table 84. Akari Therapeutics Plc Corporation Information
Table 85. Akari Therapeutics Plc Description and Business Overview
Table 86. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 87. Akari Therapeutics Plc Product
Table 88. Akari Therapeutics Plc Recent Development
Table 89. Alexion Pharmaceuticals Inc Corporation Information
Table 90. Alexion Pharmaceuticals Inc Description and Business Overview
Table 91. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 92. Alexion Pharmaceuticals Inc Product
Table 93. Alexion Pharmaceuticals Inc Recent Development
Table 94. Amgen Inc Corporation Information
Table 95. Amgen Inc Description and Business Overview
Table 96. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 97. Amgen Inc Product
Table 98. Amgen Inc Recent Development
Table 99. ChemoCentryx Inc Corporation Information
Table 100. ChemoCentryx Inc Description and Business Overview
Table 101. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 102. ChemoCentryx Inc Product
Table 103. ChemoCentryx Inc Recent Development
Table 104. greenovation Biotech GmbH Corporation Information
Table 105. greenovation Biotech GmbH Description and Business Overview
Table 106. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 107. greenovation Biotech GmbH Product
Table 108. greenovation Biotech GmbH Recent Development
Table 109. Kedrion SpA Corporation Information
Table 110. Kedrion SpA Description and Business Overview
Table 111. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Kedrion SpA Product
Table 113. Kedrion SpA Recent Development
Table 114. Omeros Corp Corporation Information
Table 115. Omeros Corp Description and Business Overview
Table 116. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Omeros Corp Product
Table 118. Omeros Corp Recent Development
Table 119. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 120. Key Challenges
Table 121. Market Risks
Table 122. Main Points Interviewed from Key Atypical Hemolytic Uremic Syndrome Drug Players
Table 123. Atypical Hemolytic Uremic Syndrome Drug Customers List
Table 124. Atypical Hemolytic Uremic Syndrome Drug Distributors List
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of FiguresFigure 1. Atypical Hemolytic Uremic Syndrome Drug Product Picture
Figure 2. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type in 2020 & 2026
Figure 3. ALN-CC5 Product Picture
Figure 4. CCX-168 Product Picture
Figure 5. ET-006 Product Picture
Figure 6. ETR-001 Product Picture
Figure 7. Mubodina Product Picture
Figure 8. OMS-72 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application in 2020 & 2026
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Others
Figure 14. Atypical Hemolytic Uremic Syndrome Drug Report Years Considered
Figure 15. Global Atypical Hemolytic Uremic Syndrome Drug Market Size 2015-2026 (US$ Million)
Figure 16. Global Atypical Hemolytic Uremic Syndrome Drug Sales 2015-2026 (K Pcs)
Figure 17. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2015-2020)
Figure 19. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region in 2019
Figure 20. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2015-2020)
Figure 21. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region in 2019
Figure 22. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Atypical Hemolytic Uremic Syndrome Drug Revenue in 2019
Figure 24. Atypical Hemolytic Uremic Syndrome Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2015-2020)
Figure 26. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type in 2019
Figure 27. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2015-2020)
Figure 28. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type in 2019
Figure 29. Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Price Range (2015-2020)
Figure 30. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2015-2020)
Figure 31. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application in 2019
Figure 32. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2015-2020)
Figure 33. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application in 2019
Figure 34. China Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate 2015-2026 (K Pcs)
Figure 35. China Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate 2015-2026 (US$ Million)
Figure 36. China Atypical Hemolytic Uremic Syndrome Drug Market Share in Global Market 2015-2026
Figure 37. China 5 and 10 Largest Atypical Hemolytic Uremic Syndrome Drug Players Market Share by Revenue in Atypical Hemolytic Uremic Syndrome Drug in 2019
Figure 38. China Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2015-2020)
Figure 39. China Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 40. China Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2015-2020)
Figure 41. China Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 42. North America Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. North America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country in 2019
Figure 45. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country in 2019
Figure 46. U.S. Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. U.S. Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Canada Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. Canada Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 51. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 52. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country in 2019
Figure 53. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country in 2019
Figure 54. Germany Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Germany Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. France Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. France Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. U.K. Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 59. U.K. Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Italy Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 61. Italy Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Russia Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. Russia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 65. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 66. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region in 2019
Figure 67. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region in 2019
Figure 68. China Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. China Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Japan Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Japan Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. South Korea Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. South Korea Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. India Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. India Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Australia Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Australia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Taiwan Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Taiwan Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Indonesia Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Indonesia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Thailand Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Thailand Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Malaysia Atypical Hemolytic Uremic Syndrome Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 85. Malaysia Atypical Hemolytic Uremic Syndrome Drug